New drug combo may reboot treatment for advanced liver cancer

NCT ID NCT07184424

Completed Disease control Sponsor: Beijing Tsinghua Chang Gung Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at 24 patients with advanced liver cancer whose disease got worse after standard treatment with lenvatinib and an immunotherapy drug. Researchers added a third drug, lenalidomide, to see if it could help control the cancer again. The goal was to measure how long patients lived without their cancer growing and overall survival. This is a small, early study, so results are not yet proven.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide
What this could lead to: If it works, this could give doctors a new way to control advanced liver cancer when standard treatments stop working.
What could go wrong: This is a very small, early study with only 24 patients and no comparison group. The results may not apply to everyone, and adding a drug can increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Beijing Tsinghua Changgung Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.